Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
Want to see CNTB full AI Analyst Report?
Total Valuation
Connect Biopharma Holdings has a market cap or net worth of $142.43M. The enterprise value is $104.78M.
Market Cap$142.43M
Enterprise Value$104.78M
Share Statistics
Connect Biopharma Holdings has 56,521,282 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding56,521,282
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Connect Biopharma Holdings’s return on equity (ROE) is -1.32 and return on invested capital (ROIC) is -135.74%.
Return on Equity (ROE)-1.32
Return on Assets (ROA)-0.99
Return on Invested Capital (ROIC)-135.74%
Return on Capital Employed (ROCE)-1.37
Revenue Per Employee1.03K
Profits Per Employee-894.84K
Employee Count62
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Connect Biopharma Holdings is ―. Connect Biopharma Holdings’s PEG ratio is -0.01.
PE Ratio―
PS Ratio2452.52
PB Ratio3.74
Price to Fair Value3.74
Price to FCF-3.04
Price to Operating Cash Flow-2.74
PEG Ratio-0.01
Income Statement
In the last 12 months, Connect Biopharma Holdings had revenue of 64.00K and earned -55.48M in profits. Earnings per share was -1.00.
Revenue64.00K
Gross Profit64.00K
Operating Income-58.07M
Pretax Income-55.28M
Net Income-55.48M
EBITDA-57.37M
Earnings Per Share (EPS)-1.00
Cash Flow
In the last 12 months, operating cash flow was -51.21M and capital expenditures -434.00K, giving a free cash flow of -51.64M billion.
Operating Cash Flow-51.21M
Free Cash Flow-51.64M
Free Cash Flow per Share-0.91
Dividends & Yields
Connect Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.35
52-Week Price Change211.11%
50-Day Moving Average2.77
200-Day Moving Average2.21
Relative Strength Index (RSI)48.71
Average Volume (3m)97.97K
Important Dates
Connect Biopharma Holdings upcoming earnings date is May 14, 2026, After Close (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 14, 2026
Ex-Dividend Date―
Financial Position
Connect Biopharma Holdings as a current ratio of 3.74, with Debt / Equity ratio of 1.64%
Current Ratio3.74
Quick Ratio3.74
Debt to Market Cap0.00
Net Debt to EBITDA0.66
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Connect Biopharma Holdings has paid 197.00K in taxes.
Income Tax197.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Connect Biopharma Holdings EV to EBITDA ratio is -2.08, with an EV/FCF ratio of -2.31.
EV to Sales1.86K
EV to EBITDA-2.08
EV to Free Cash Flow-2.31
EV to Operating Cash Flow-2.33
Balance Sheet
Connect Biopharma Holdings has $44.34M in cash and marketable securities with $690.00K in debt, giving a net cash position of $43.65M billion.
Cash & Marketable Securities$44.34M
Total Debt$690.00K
Net Cash$43.65M
Net Cash Per Share$0.77
Tangible Book Value Per Share$0.75
Margins
Gross margin is 100.00%, with operating margin of -90740.63%, and net profit margin of -86687.50%.
Gross Margin100.00%
Operating Margin-90740.63%
Pretax Margin-86379.69%
Net Profit Margin-86687.50%
EBITDA Margin-89640.63%
EBIT Margin-90740.63%
Analyst Forecast
The average price target for Connect Biopharma Holdings is $8.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.38
Price Target Upside198.04% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―